Content
01/13/2025
New Haven, CT USA
Normunity
completed $75 million Series B Round funding. Investors include
Samsara BioCapital (lead), Enavate Sciences (lead), Canaan Partners, Connecticut Innovations, HongShan Capital Group, Osage Venture Partners, Pfizer Ventures, Regeneron Ventures, Sanofi Ventures, Taiho Ventures, YK Bioventures.
About
Normunity is a biotechnology company creating novel anti-cancer therapies that address untapped biology at the interface of the immune system and the tumor to target mechanisms that impact tumor growth and circumvent immune surveillance and tumor clearance. The company is using these novel targets to build a pipeline of anti-cancer medicines, including therapeutic antibodies, bispecific antibodies, and payload-carrying biologics. The company's lead program, NRM'823, is a T cell engager with tumor-specific targeting for multiple solid tumors and is expected to enter the clinic in 2025.
Startup
Sector:
Biotech
Life Science
Download StockFan App
Ad
Stock market data, news and community, all integrated.
Features include real time stock quotes, interactive charts, technical signals, institutional & insider ownerships, stock screener, ETF rankings, SEC filings, press releases, videos, earnings calendar, social media posts, group chats.
